04/12/2017 12:01:03

Arix Bioscience leads $30 million financing for Atox Bio

Related content
10 Oct - 
Update on LogicBio proposed IPO in the United States
01 Oct - 
Co-leads $58 million Series A for VelosBio
26 Sep - 
LogicBio files registration for proposed IPO in the US

Arix Bioscience leads $30 million financing for Atox Bio

Funding to

advance Reltecimod into a Phase 2 clinical study for acute kidney injury, building upon Atox Bio's on-going Phase 3 clinical development in necrotising soft tissue infections

Arix achieves target of 12 Group Businesses by the end of 2017, successfully building a balanced group with multiple, potentially significant milestones over the next 12 months

LONDON, 4 December 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience" or "Arix"), a global healthcare and life science company supporting medical innovation, today announces that it has led an oversubscribed $30 million Series F financing round for Atox Bio. Atox Bio is a late stage clinical biotechnology company developing novel immune modulators for critically ill patients with severe infections including necrotising soft tissue infections (NSTI) and acute kidney injury (AKI).

The $30 million fundraising led by Arix Bioscience included new investors Adams Street Partners, Asahi Kasei Corporation and additional undisclosed investors, alongside existing investors SR One, OrbiMed, Lundbeckfonden Ventures, Becker and Integra Holdings.

Arix Bioscience is investing $8 million for an equity stake in Atox Bio. As part of the financing, Arix Bioscience's Jonathan Tobin will join Atox Bio's Board of Directors.

Atox Bio's lead therapeutic candidate, Reltecimod, is a novel peptide that modulates the body's immune response, lowering the risk of potential morbidities and mortality. Reltecimod received Orphan Drug status from the FDA and EMA as well as Fast Track designation. Atox Bio is conducting a Phase 3 clinical study of Reltecimod for patients with NSTIs, and will start a Phase 2 clinical study for AKIs in 2018.

Joe Anderson, Chief Executive Officer of Arix Bioscience, commented: "We are pleased to have led this successful financing round for Atox Bio, which is developing therapies for severe, potentially life-threatening conditions in the critical care setting where no other therapies exist. Necrotising soft tissue infections and acute kidney injury are major unmet medical needs, and we look forward to supporting the company to develop treatments that would be potentially life-changing for patients.

"With this high quality deal, Arix Bioscience has met the target we set out at our IPO to have 12 Arix Group Businesses by the end of 2017. Over the coming months, our Group Businesses will reach multiple, potentially significant milestones which, if successful, will support the further development of breakthrough innovation for patients and value for shareholders."

Dan Teleman, Chief Executive Officer of Atox Bio, commented: "We are excited to welcome such high quality investors into the existing strong syndicate. The success of this round reflects the significant achievements we have made to date in the development of Reltecimod and recognition of the critical unmet medical need for treatments for NSTI and AKI."

For more information, please contact:

Arix Bioscience plc

Joe Anderson, CEO

+44 (0)20 7290 1052

Matthew Cole, Communications Director

+44 (0)20 7290 1065

Consilium Strategic Communications

Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan

+44 (0)20 3709 5700


About Arix Bioscience plc

Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.

Arix Bioscience plc is listed on the Main Market of the London Stock Exchange.

For further information, please visit www.arixbioscience.com

About Atox Bio

Atox Bio is a late stage clinical biotechnology company with operations in the US and Israel that develops novel immune modulators for critically ill patients with severe infections. Atox Bio has an ongoing contract with the Biomedical Advanced Research and Development Authority (BARDA) supporting the development of Reltecimod in NSTI. Atox Bio was established by Prof. Raymond Kaempfer and Dr. Gila Arad from the Hebrew University of Jerusalem and Yissum.

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
IMRALDI™, Biogen’s Adalimumab Biosimilar Referencing Humira®, Is Launched in the European Union
Glance Reports Third Quarter 2018 Results
Axiom Real-Time Metrics Exhibiting at OCT Pacific Northwest in Vancouver
Ctrip and KLM Sign Strategic Partnership Agreement
Atos and Siemens team up to enable enterprises to deploy IoT applications on private Cloud

Related stock quotes

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Berlingske Media 2018  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
18 October 2018 00:16:06
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20181005.3 - EUROWEB6 - 2018-10-18 01:16:06 - 2018-10-18 00:16:06 - 1000 - Website: OKAY